Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

Cited by (173)

Items 101–173 of 173

1. PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
   Wei Liu, Chunyu Wang, Shengli Wang, Kai Zeng, Shan Wei, Ning Sun, Ge Sun, Manlin Wang, Renlong Zou, Wensu Liu et al. · 2020 · International Journal of Biological Sciences
2. Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
   Furong Huang, Kexin Li, Jeffrey W. Shevach, Qianben Wang · 2025 · Journal of the National Cancer Center
3. Prostate cancer in omics era
   Nasrin Gholami, Amin Haghparast, Iraj Alipourfard, Majid Nazari · 2022 · Cancer Cell International
4. Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development
   Kimberley Katleba, P. Ghosh, Maria M. Mudryj · 2023 · Biomedicines
5. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer
   Mark L. Daniel, Todd Philip Knutson, Jamie M. Sperger, Yingming Li, Anupama Singh, Charlotte N. Stahlfeld, Courtney N. Passow, Benjamin Auch, Joshua Michael Lang, Scott M. Dehm · 2021 · Endocrine Related Cancer
6. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
   A. M. Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, Anuradha Jayaram, Stephen Q. Wong, Scott Williams, Anupama Pasam, Anna Trigos, Blanca Trujillo, Emily Grist et al. · 2023 · Nature Communications
7. Allosteric alterations in the androgen receptor and activity in prostate cancer
   Takuma Uo, Stephen R. Plymate, Cynthia C.T. Sprenger · 2017 · Endocrine Related Cancer
8. Androgen receptor and estrogen receptor variants in prostate and breast cancers
   José C. Valentín López, Carol Ann Lange, Scott M. Dehm · 2024 · The Journal of Steroid Biochemistry and Molecular Biology
9. AR-Variant–Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
   Scott M. Dehm, Bruce Montgomery, Stephen R. Plymate · 2018 · Clinical Cancer Research
10. Alternative splicing regulation by the androgen receptor in prostate cancer cells
    Lucas Germain, Camille Lafront, Jolyane Beaudette, Raghavendra Tejo Karthik Poluri, Cindy Weidmann, Étienne Audet‐Walsh · 2020 · The Journal of Steroid Biochemistry and Molecular Biology
11. The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts
    Cinzia Caggiano, Marco Pieraccioli, Consuelo Pitolli, Gabriele Babini, Dinghai Zheng, Bin Tian, Pamela Bielli, Claudio Sette · 2022 · Nucleic Acids Research
12. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy
    Masaki Shiota, Miho Ushijima, Kenjiro Imada, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Katsunori Tatsugami, Shunichi Kajioka, Masatoshi Eto · 2019 · The Prostate
13. Stat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling
    Cristina Maranto, Lavannya Sabharwal, Vindhya Udhane, Samuel P. Pitzen, Braedan M. McCluskey, Songyan Qi, Christine L. O’Connor, Savita Devi, Scott C. Johnson, Kenneth M. Jacobsohn et al. · 2024 · Science Advances
14. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
    Li, Haolong, Melnyk, James E., Fu, Becky Xu Hua, Shrestha, Raunak, Zhang, Meng, Sjöström, Martin, Feng, Siyu, Anderson, Jasmine A., Han, Wanting, Chesner, Lisa N. et al. · 2025 · Nature Genetics
15. Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer
    Diwei Zhao, Zijun Mo, Tianyou Zhang, Xinyang Cai, Zhenyu Yang, Dong Chen, Junliang Zhao, Y. Li, Fangjian Zhou, Zhen Li et al. · 2026 · Science Advances
16. Deciphering Complexity
    Giuseppe Nicolò Fanelli, Pier Vitale Nuzzo, Filippo Pederzoli, Massimo F. Loda · 2024 · Surgical pathology clinics
17. Targeting the CLK 2/ SRSF 9 splicing axis in prostate cancer leads to decreased ARV 7 expression
    Jasper Van Goubergen, Miroslav Peřina, Florian Handle, Elisa Morales, Anika Kremer, Oliver Schmidt, G. Kristiansen, Marcus Victor Cronauer, Frederic Romain Santer · 2024 · Molecular Oncology
18. The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
    Emmy Boerrigter, Guillemette Emma Benoist, Joanneke K. Overbeek, Rogier Donders, Niven Mehra, Inge M. van Oort, Rob ter Heine, Nielka P. van Erp · 2021 · British Journal of Clinical Pharmacology
19. Genetics of Prostate Carcinoma
    Božo Krušlin, Lucija Škara, Tonći Vodopić, Borna Vrhovec, Jure Murgić, Goran Štimac, Ana Fröbe, Cvjetko Lež, Monika Ulamec, Koraljka Gall‐Tros̆elj · 2021 · Acta Medica Academica
20. Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7–positive prostate cancer cells
    Atsuhiko Yoshizawa, Kiyoshi Takahara, Masanobu Saruta, Kenji Zennami, Takuhisa Nukaya, Kosuke Fukaya, Manabu Ichino, Naohiko Fukami, Atsuko Niimi, Hitomi Sasaki et al. · 2020 · Prostate International
21. AR Structural Variants and Prostate Cancer
    Laura Cato, Maysoun Shomali · 2022 · Advances in experimental medicine and biology
22. Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
    Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James Robert Bischoff, Georges Habineza et al. · 2021 · Molecular Cancer Therapeutics
23. Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
    Radu Costin Bizga Nicolescu, Zoe R. Maylin, Francisco Javier Pérez-Areales, Jessica Iegre, Hardev Pandha, Mohammad Asim, David R. Spring · 2022 · ChemMedChem
24. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
    Eva Chrenková, Hana Študentová, Kateřina Holá, Zuzana Kahounová, Romana Hendrychová, Karel Souček, Jan Bouchal · 2024 · Frontiers in Oncology
25. Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC)
    Ashish Tyagi, Balaji Chandrasekaran, Vaibhav Shukla, Neha Tyagi, Arun Kumar Sharma, Chendil Damodaran · 2024 · Pharmacology & Therapeutics
26. Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer
    Susan Halabi, Siyuan Guo, Bin Luo, Chenxi Yu, Todd Philip Knutson, Anna Kobilka, Jacqueline Lyman, Himisha Beltran, Emmanuel S. Antonarakis, Matthew D. Galsky et al. · 2025 · European Urology
27. Extra-nuclear and cytoplasmic steroid receptor signalling in hormone dependent cancers
    Stephanie Agbana, Marie McIlroy · 2024 · The Journal of Steroid Biochemistry and Molecular Biology
28. Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Mayao Luo, Yifan Zhang, Zhuofan Xu, Chenwei Wu, Yuedian Ye, Rui Liu, Shidong Lv, Qiang Wei · 2022 · Cell Death Discovery
29. Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.
    Min Liu, Hongzhe Shi, Jiaqing Yan, Yuan Zhang, Yinglin Ma, Kaidi Le, Zhongdong Li, Nianzeng Xing, Guohui Li · 2021 · PubMed Central
30. Differential expression of androgen receptor variants in hormone‐sensitive prostate cancer xenografts, castration‐resistant sublines, and patient specimens according to the treatment sequence
    Mariko Honda, Takahiro Kimura, Yuko Kamata, Kojiro Tashiro, Shoji Kimura, Yusuke Koike, Shun Sato, Takashi Yorozu, Bungo Furusato, Hiroyuki Takahashi et al. · 2019 · The Prostate
31. Reply to L. Dirix, B. De Laere et al, and A. Sharp et al
    Andrew J. Armstrong, Susan Halabi, Jun Luo, David M. Nanus, Howard I. Scher, Emmanuel S. Antonarakis, Daniel J. George · 2019 · Journal of Clinical Oncology
32. Systems-level liquid biopsy in advanced prostate cancer
    Jacque A. Lyman, Scott M. Dehm · 2025 · Endocrine Related Cancer
33. Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
    Mitchell G. Lawrence, Shivakumar Keerthikumar, Scott L. Townley, Ashlee K. Clark, Georgia B. Cuffe, Geraldine Laven‐Law, Adrienne R. Hanson, Raj Kumar Shrestha, Todd Philip Knutson, Michelle G. Richards et al. · 2025 · European Urology Focus
34. Identification of Two Types of Stem Cells in Methylene Blue-stained Sections of Untreated and Diethylstilbestrol-treated Human Prostate Cancer and Their Characterization by Immunogold Localization of CD133
    Akhouri A. Sinha, Michael J. Wilson · 2018 · Anticancer Research
35. Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
    Alexander William Wyatt, Gillian Rae Vandekerkhove · 2020 · Société Internationale d’Urologie Journal
36. Identification of a novel C-terminally truncated estrogen receptor α variant (ERαi34) with constitutive transactivation and estrogen receptor antagonist resistance
    Hirotaka Ishii, Yujiro Hattori, Hitoshi Ozawa · 2019 · Molecular and Cellular Endocrinology
37. Evolution of AR and Non- AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
    José C. Valentín López, Chenxi Yu, Todd Philip Knutson, Anna Kobilka, Jacque A. Lyman, Siyuan Guo, Bin Luo, Sarah A. Munro, YINGMING LI, Rakesh Heer et al. · 2026 · Clinical Cancer Research
38. Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate
    Maaike A. C. Bruin, Ma Ida Mohmaed Ali, Merel van Nuland, Bart Jacobs, Luc Lucas, Vincent Olaf Dezentjé, Jeantine M. de Feijter, Hilde Rosing, Andries Marinus Bergman, Jos H. Beijnen et al. · 2023 · Pharmaceutical Research
39. Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer (Review)
    Lithip Gandupalli, Doulat Bhowmik, Charmi Jyotishi, Reeshu Gupta · 2025 · World Academy of Sciences Journal
40. Hormone-Responsive Cancers
    Myles A Brown, Laura Cato, Rinath M. Jeselsohn · 2019 · Elsevier eBooks
41. Evolution of the prostate cancer genome towards resistance
    Francesca Lorenzin, Francesca Demichelis · 2019 · Journal of Translational Genetics and Genomics
42. Prostate cancer germline variants with therapeutic implications
    Masoud Bitaraf, Elena Castro, Nima Sharifi · 2025 · Trends in Molecular Medicine
43. The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain
    Claire L. Soave, Charles E. Ducker, Naeyma N. Islam, Seongho Kim, Sally M. Yurgelevic, Nathan I. Nicely, Luke Pardy, Yanfang Huang, Peter E. Shaw, Gregory W. Auner et al. · 2023 · Molecular Pharmacology
44. The effect of HMGB1 and RAGE on the clinicopathological and prognostic features of prostate cancer
    Daojun Lv · 2021 · Journal of Translational Genetics and Genomics
45. Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer
    Zahraa Saker, Mahdi Rizk, Sanaa M. Nabha · 2023 · Elsevier eBooks
46. A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer
    Jones Trevor Nauseef, Timothy R. Chu, William F. Hooper, Alicia Alonso, Ali Oku, Heather M. Geiger, Zoe R. Goldstein, Minita J. Shah, Michael Sigouros, Jyothi Manohar et al. · 2025 · npj Precision Oncology
47. Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?
    Joaquı́n Mateo, Adam Sharp, Johann Sebastian De Bono · 2017 · European Urology
48. Clinical Significance of AR-V567es in Prostate Cancer—Letter
    Takuma Uo, Stephen R. Plymate · 2019 · Clinical Cancer Research
49. Advances in metastatic prostate cancer circulating tumor cell enrichment technologies and clinical studies
    Naira Essam Abou-Ghali, Paraskevi Giannakakou · 2024 · International review of cytology
50. Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers
    Alec Paschalis, Ines Figueiredo, Denisa Bogdan, Arian Lundberg, Rita Santos, Bora Gürel, Tarek Taha, Ossian Longoria, Ana Ferreira, Claudia Bertan et al. · 2026 · Journal of Clinical Investigation
51. Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study
    Sawkar Vijay Pramod, Ferry Safriadi, Bethy Surjawathy Hernowo, Reiva Farah Dwiyana, Nurvita Trianasari, Shinichi Egawa · 2023 · Research and Reports in Urology
52. Acquiring evidence for precision prostate cancer care
    Joaquı́n Mateo, Suzanne Carreira, Johann Sebastian De Bono · 2017 · Annals of Oncology
53. Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progression
    Siddappa Manjunath, Sajad A. Wani, Mark D. Long, Damien A. Leach, Ewy A. Mathé, Charlotte Lynne Bevan, Moray J. Campbell · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
54. Quantitative expression data of human estrogen receptor α variants in non-functioning pituitary adenomas obtained by reverse transcription-digital polymerase chain reaction analysis
    Yujiro Hattori, Hirotaka Ishii, Shigeyuki Tahara, Akio Morita, Hitoshi Ozawa · 2020 · Data in Brief
55. The multifaceted roles of serine/arginine repetitive matrix 4 in the development of neuroendocrine prostate cancer
    Ahn R. Lee · 2019 · cIRcle (University of British Columbia)
56. Faculty Opinions recommendation of ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Patricia V. Elizalde · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
57. Avaliação da expressão gênica dos coativadores da família p160 na progressão do carcinoma prostático
    Poliana Romão da Silva · 2022
58. Designed Ankyrin Repeat Proteins for detecting prostate-specific antigen expression in vivo
    Melanie Gut, Birgit Dreier, Sven Furler, Jens Sobek, Andreas Plückthun, Jason P. Holland · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
59. Data from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
    Matti Annala, Sinja Taavitsainen, Daniel Joseph Khalaf, Gillian Rae Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W. Warner, Cameron Herberts, Amanda Wong, Simon Yuen Fai Fu et al. · 2023
60. Data from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
    Hanna Tukachinsky, Russell William Madison, Jon Chung, Ole V. Gjoerup, Eric Allan Severson, Lucas M. Dennis, Bernard J. Fendler, Samantha Morley, Lei Zhong, Ryon P. Graf et al. · 2023
61. Data from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
    Hanna Tukachinsky, Russell William Madison, Jon Chung, Ole V. Gjoerup, Eric Allan Severson, Lucas M. Dennis, Bernard J. Fendler, Samantha Morley, Lei Zhong, Ryon P. Graf et al. · 2023
62. Supplementary Data 3 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
    Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James Robert Bischoff, Georges Habineza et al. · 2023
63. Molekulare Mechanismen der Resistenzentstehung und pathologische Aspekte der Therapieplanung beim Prostatakarzinom
    Verena Sailer, Sven Perner · 2023 · Springer eBooks
64. Research Progress of AR Gene Family in Prostate Cancer Therapy
    Maham Khan · 2024 · annals of urologic oncology
65. Cell‐ ELISA ‐Based High‐Throughput Screening Leads to the Discovery of Androgen Receptor Degraders to Conquer Castration‐Resistant Prostate Cancer
    Yang Ji, Meng Yin Wu, Haojia Dong, Rongyu Zhang, Huirong Chen, Hui Mao, Xiaoli Han, Zhenghao Chen, Jinming Zhou · 2025 · The FASEB Journal
66. Additional file 1 of Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
    Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Fornarini, Giuseppe, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli et al. · 2022 · Figshare
67. Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment
    Lisanne N. van Merendonk, Maud B. A. van der Kleij, Andries Marinus Bergman, Huub H. van Rossum, Neeltje Steeghs, Alwin D. R. Huitema · 2026 · Therapeutic Drug Monitoring
68. Calcium Channels in Prostate Cancer Drug Resistance
    Dheeraj Kannancheri Puthooru · 2025 · theses.fr (ABES)
69. A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer
    Claire L. Soave, Lisa Polin, Charles E. Ducker, Vy Ong, Seongho Kim, Luke Pardy, Jing Li, Xun Bao, Yanfang Huang, Peter E. Shaw et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
70. Long noncoding RNAs mediate endocrine signaling and resistance in prostate cancer
    Daniel G. Gioeli · 2026 · Endocrinology
71. Targeted proteomics for the detection of androgen receptor variants in preclinical models of castration-resistant prostate cancer
    Zoi E. Sychev, Gabrianne Larson, Megan Ludwig, Seiei Shiba, Kiel T. Tietz, Joshua W. Russo, Steven P. Balk, Eva Corey, Stephen Plymate, Emmanuel S. Antonarakis et al. · 2026 · Clinical Proteomics
72. The role of molecular profiling for castration-resistant prostate cancer treatment and therapy development
    Timothy J. Mann, Therese M. Becker, Tara Laurine Roberts, Paul DE SOUZA, John George Lock · 2026 · Frontiers in Cell and Developmental Biology
73. Dual-target regulation of prostate cancer genetic dependencies by a programmable tetrahedral DNA nanostructure.
    Zhen Hang, Hong-Kai Wang, Liu Yu, Shi-Wei Liu, Wei Zhang, Tao Feng, Yong-Qing Zhang, Xi-Yue Xiao, Wen-Hao Xu, Ding-Wei Ye et al. · 2026 · Cancer Genetics